The Food and Drug Administration today released a final rule regulating certain protein products, such as insulin, as biological products rather than drugs effective March 23. Authorized by the Biologics Price Competition and Innovation Act of 2009, the change will allow new insulin products, and certain other protein products, to apply for marketing approval through the abbreviated pathway for biosimilar or interchangeable products in an effort to increase market competition and lower prices. For more on the change, see the FDA FAQs for health care providers and patients

In other news, FDA today released a table of gene-drug interactions based on FDA labeling and other scientific evidence, which it plans to update periodically to aid prescribers. 
 

Related News Articles

Headline
A report from AARP and the National Alliance for Caregiving released today found nearly 1 in 4 U.S. adults (63 million) are caring for an adult or child…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., July 19 visited AtlantiCare health system in New Jersey, making stops at its…
Headline
The House has begun consideration of the Senate-passed version of the One Big Beautiful Bill Act (H.R. 1). This continues to be a fluid…
Headline
The Departments of Justice and Health and Human Services today announced the creation of the DOJ-HHS False Claims Act Working Group to combat health care fraud…
Headline
The Centers for Medicare & Medicaid Services today announced it has identified a fraud scheme targeting Medicare providers and suppliers. CMS said scammers…
Headline
The Senate Health, Education, Labor, and Pensions Committee today released its text for the budget reconciliation bill. The text includes one health care…